Cambridge-based Sarepta Therapeutics said it was halting shipments of its Duchenne muscular dystrophy gene therapy for ...

Sarepta Therapeutics ( NASDAQ: SRPT) fell ~38% in the premarket on Monday after the company reported a second fatality from ...

Sarepta’s shares crashed 41% in pre-market trading Monday morning to $21.01 after the biotech reported a second death from ...

Genetic study identifies FOXP4 as a key factor in long COVID, emphasizing the importance of diverse population inclusion.

Researchers discovered a previously unknown function of RNA, potentially opening the door to new ways to treat cancer and ...

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

Researchers say they have finally confirmed the cancer-stopping gene found in elephants and several other animals.

Sarepta halts Elevidys shipments for non-ambulatory DMD patients after a second patient death in three months post gene ...

Shares of Sarepta Therapeutics plunged 34% in premarket trading on Monday, a day after the company disclosed a second case of patient death due to acute liver failure after receiving its gene therapy ...

In a 2015 study BGR reported that researchers discovered that elephants possess 19 extra copies of the TP53 gene, a powerful ...

Gene Deal criticized Kanye West’s courthouse appearance at Diddy’s trial as “stupid” and warned it could damage his legal ...

Another person treated with Elevidys suffered acute liver failure, leading Sarepta to discontinue treatment in certain patients while it evaluates new safety precautions.